Tvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James Financial

Research analysts at Raymond James Financial began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) in a research note issued on Monday,Briefing.com Automated Import reports. The firm set an "outperform" rating and a $62.00 price target on the stock. Raymond James Financial's price target would suggest a potential upside of 126.77% from the company's previous close.

TVRD has been the subject of several other research reports. Wall Street Zen upgraded shares of Tvardi Therapeutics to a "hold" rating in a research note on Saturday, May 24th. Cantor Fitzgerald began coverage on shares of Tvardi Therapeutics in a research note on Friday. They issued an "overweight" rating and a $52.00 target price for the company. Oppenheimer began coverage on shares of Tvardi Therapeutics in a report on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 price target for the company. Finally, Piper Sandler began coverage on shares of Tvardi Therapeutics in a report on Thursday, June 12th. They issued an "overweight" rating and a $78.00 price target for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Tvardi Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $64.25.

Tvardi Therapeutics Stock Up 20.6%

Shares of NASDAQ:TVRD opened at $27.34 on Monday. Tvardi Therapeutics has a 1-year low of $8.13 and a 1-year high of $34.31.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.